Episode 26. Management of Newly Diagnosed Hodgkin's Lymphoma
Blood Cancer Talks
00:00
The Cost of NIVO AVD
The third trial which the message is less clear perhaps from this trial but also very impressive cooperative group study presented recently. Phil Rouge was led by the Italian Lymphoma Group and they took 500 patients and randomized them to either receive pet adapted ABVD, alarathal or six cycles of dose intensified ABVD. Now interestingly they did show an improved three year progression per survival of 86.7% compared to 73%. But I couldn't see much in the presentation in terms of cardiotoxicity specific data which I'm sure will come with a full paper. So yes I'm very keen to hear what you think and have these results and have a if at all you know we'll impact things
Transcript
Play full episode
